Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression

Thrombosis Research

Volumn 122, Issue 6, 2008, Pages 854-860

  Ramón, Luis A ^a   Gilabert Estellés, Juan ^a   Cosín, Raul ^a   Gilabert, Juan ^b   España, Francisco ^a   Castelló, Remedios ^a   Chirivella, Melitina ^a   Romeu, Alberto ^a   Estellés, Amparo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Endometriosis; Fibrinolysis; PAI 1 4G 5G polymorphism; PAI 1mRNA; Plasminogen activator inhibitor 1 (PAI 1)

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; ASCITIC FLUID; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RNA, MESSENGER;

EID: 52049125957     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.02.010     Document Type: Article

References (34)

1. Bruse C., Bergqvist A., Carlstrom K., Fianu-Jonasson A., Lecander I., and Astedt B. Fibrinolytic factors in endometriotic tissue, endometrium, peritoneal fluid, and plasma from women with endometriosis and in endometrium and peritoneal fluid from healthy women. Fertil Steril 70 (1998) 821-826
2. Lembessis P., Milingos S., Michalas S., Milingos D., Creatsas G., Sourla A., et al. Urokinase-type plasminogen activator and insulin-like growth factor-binding protein 3 mRNA expression in endometriotic lesions and eutopic endometrium: Implications for the pathophysiology of endometriosis. Ann N Y Acad Sci 997 (2003) 223-228
3. Gilabert-Estellés J., Estellés A., Gilabert J., Castelló R., España F., Falcó C., et al. Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. Hum Reprod 18 (2003) 1516-1522
4. Gilabert-Estellés J., Ramón L.A., España F., Gilabert J., Vila V., Réganon E., et al. Expression of angiogenic factors in endometriosis: Its relation to fibrinolytic and metalloproteinase (MMP) systems. Hum Reprod 22 (2007) 2120-2127
5. Loskutoff D. Regulation of PAI-1 gene expression. Fibrinolysis 5 (1991) 197-206
6. Andreasen P.A., Georg B., Lund L.R., Riccio A., and Stacey S.N. Plasminogen activator inhibitors: Hormonally regulated serpins. Mol Cell Endocrinol 68 (1990) 1-19
7. Estellés A., Gilabert J., Keeton M., Eguchi Y., Aznar J., Grancha S., et al. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 84 (1994) 143-150
8. Pellicer A., Navarro J., Bosch E., Garrido N., García-Velasco J.A., Remohí J., et al. Endometrial quality in infertile women with endometriosis. Ann N Y Acad Sci 943 (2001) 122-130
9. Castelló R., Estellés A., Vázquez C., Falcó C., España F., Almenar S.M., et al. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator Inhibitor type 1 (PAI-1) and tissue metalloproteinase inhibitor type 1 (TIMP-1) gene expression in primary breast cancer. Clin Chem 48 (2002) 1288-1295
10. Harbeck N., Kruger A., Sinz S., Kates R.E., Thomssen C., Schmitt M., et al. Clinical relevance of the plasminogen activator inhibitor type 1, a multifaceted proteolytic factor. Onkologie 24 (2001) 238-244
11. Alessi M.C., Juhan-Vague I., Kooistra T., Declerck P.J., and Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 60 (1988) 491-494
12. Loskutoff D.J., Sawdey M., Keeton M., and Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb Haemost 70 (1993) 135-137
13. Henry M., Chomiki N., Scarabin P.Y., Alessi M.C., Peiretti F., Arveiler D., et al. Five frequent polymorphisms of the PAI-1 gene: Lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 17 (1997) 851-858
14. Eriksson P., Kallin B., van 't Hooft F.M., Bavenholm P., and Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92 (1995) 1851-1855
15. Roncal C., Orbe J., Rodriguez J.A., Belzunce M., Beloqui O., Diez J., et al. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovasc Res 63 (2004) 176-185
16. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., and Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268 (1993) 10739-10745
17. Grancha S., Estellés A., Tormo G., Falcó C., Gilabert J., España F., et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 81 (1999) 516-521
18. Solá E., Vayá A., España F., Castelló R., Ramón L.A., Hernández-Mijares A., et al. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. Thromb Res (2007) [Electronic publication ahead of print]
19. Tsantes A.E., Nikolopoulos G.K., Bagos P.G., Bonovas S., Kopterides P., and Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res (Oct 17 2007) [Electronic publication ahead of print]
20. Castelló R., España F., Vázquez C., Fuster C., Almenar S.M., Aznar J., et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in human breast cancer and its association with tissue PAI-1 levels and severity tumor grade. Thromb Res 117 (2006) 487-492
21. Bedaiwy M.A., Falcone T., Mascha E.J., and Casper R.F. Genetic polymorphism in the fibrinolytic system and endometriosis. Obstet Gynecol 108 (2006) 162-168
22. American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine Classification of endometriosis: 1996. Fertil Steril 67 (1997) 817-821
23. Ramón L., Gilabert-Estellés J., Castelló R., Gilabert J., España F., Romeu A., et al. mRNA quantitative analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using real-time reverse transcription-PCR assay. Hum Reprod 20 (2005) 272-278
24. Castelló R., Landete J.M., España F., Vázquez C., Fuster C., Almenar S.M., et al. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb Res 120 (2007) 753-762
25. Bruse C., Radu D., and Bergqvist A. In situ localization of mRNA for the fibrinolytic factors uPA, PAI-1 and uPAR in endometriotic and endometrial tissue. Mol Hum Reprod 10 (2004) 159-166
26. Gilabert-Estellés J., Castelló R., Gilabert J., Ramón L.A., España F., Romeu A., et al. Plasminogen activators and plasminogen activator inhibitors in endometriosis. Front Biosci 10 (2005) 1162-1176
27. Gilabert-Estellés J., Ramón L.A., España F., Gilabert J., Castelló R., and Estellés A. Expression of fibrinolytic components in endometriosis. Pathophysiol Haemost Thromb 35 (2006) 136-140
28. Hellebrekers B.W., Emeis J.J., Kooistra T., Trimbos J.B., Moore N.R., Zwinderman K.H., et al. A role for the fibrinolytic system in postsurgical adhesion formation. Fertil Steril 83 (2005) 122-129
29. Sharpe-Timms K.L. Endometrial anomalies in women with endometriosis. Ann N Y Acad Sci 943 (2001) 131-147
30. Folsom A.R., Cushman M., Heckbert S.R., Rosamond W.D., and Aleksic N. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol 56 (2003) 598-603
31. Mattes D., Weger M., Renner W., Cichocki L., and Haas A. Role of angiotensin-converting enzyme insertion/deletion and plasminogen activator inhibitor-1 4G/5G gene polymorphisms in retinal vein occlusion. J Thromb Haemost 3 (2005) 2583-2584
32. Seguí R., Estellés A., Mira Y., España F., Villa P., Falcó C., et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111 (2000) 122-128
33. Wiklund P.G., Nilsson L., Ardnor S.N., Eriksson P., Johansson L., Stegmayr B., et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: Replicated findings in two nested case-control studies based on independent cohorts. Stroke 36 (2005) 1661-1665
34. Koninckx P.R., Kennedy S.H., and Barlow D.H. Endometriotic disease: The role of peritoneal fluid. Hum Reprod Update 4 (1998) 741-751